Table 4 The comparison between ASCL2 and other EMT biomarkers.

From: ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3

Study PMID

Gene

Validation cohort

Prediction accuracy

Mechanism exploration

40,634,441

NOX4

NA

NA

NA

37,304,008

EZR

Three (n = 2091)

0.693

NA

36,620,876

CBX3

NA

0.664

NA

30,602,372

PRAME

NA

NA

NA

NA

ASCL2

Four (n = 2245)

0.728

Synergistic function of CLDN3

  1. NA, not applicable.